CHO Pharma

CHO Pharma FCF Margin

The Free Cash Flow Margin of CHO Pharma (6586.TWO) as of Nov 1, 2026 is -20,354.30 %. In the previous year, Free Cash Flow Margin was -6,225.53 % — a change of 226.95% (lower).

FCF Margin

-20,354.30 %

YoY

226.95%

Last updated:

Free Cash Flow Margin of CHO Pharma is 2025 -20,354.30 % . Free Cash Flow Margin of CHO Pharma was 2024 -6,225.53 % . It decreases by 226.95% lower compared to the previous year.

The CHO Pharma FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2017
-64,712.88 TWD
Jan 1, 2018
-85,354.83 TWD
Jan 1, 2019
-93,653.87 TWD
Jan 1, 2020
-196,295.65 TWD
Jan 1, 2021
-5,493.25 TWD
Jan 1, 2022
-431,501.67 TWD
Jan 1, 2024
-6,225.53 TWD
Jan 1, 2025
-20,354.30 TWD
The CHO Pharma FCF Margin history
YEARFCF MarginYoY
-20,354.30 %+226.95%
-6,225.53 %-98.56%
-431,501.67 %+7,755.13%
-5,493.25 %-97.20%
-196,295.65 %+109.60%
-93,653.87 %+9.72%
-85,354.83 %+31.90%
-64,712.88 %+594.16%
-9,322.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

CHO Pharma Stock analysis

What does CHO Pharma do? CHO Pharma, Inc. develops and commercializes innovative biopharmaceutical products using proprietary glycan engineering technologies. The company focuses on eight technology categories: homogeneous antibody drugs, monoclonal antibodies for cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, Saccharin tablets, sugar probes, sugar molecular synthesis and identification, and derivative patents of innovation development plans. These products are targeted at medical and pharmaceutical markets requiring advanced therapeutic solutions. The company's revenue streams come from the development and commercialization of these specialized biopharmaceutical products. Its primary customers are healthcare providers, hospitals, and pharmaceutical distributors seeking advanced treatments for cancer, immune disorders, and infectious diseases. The company's technology segments include antibody therapies, vaccine development, and antiviral drug applications, all leveraging its glycan engineering platform. CHO Pharma's business model centers on leveraging its patented glycan engineering technologies to create and sell high-value pharmaceutical products. The company's product portfolio spans multiple therapeutic areas, including oncology, immunology, and virology, with a focus on developing innovative treatments that address unmet medical needs. Its commercialization strategy involves direct sales to healthcare institutions and partnerships with pharmaceutical distributors for broader market reach. CHO Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CHO Pharma stock

Free Cash Flow Margin of CHO Pharma is -20,354.30 % in 2025.

Free Cash Flow Margin of CHO Pharma changed from -6,225.53 % to -20,354.30 %, representing a 226.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin CHO Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's CHO Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — CHO Pharma

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — CHO Pharma